DDInter1130 DDInter1376
A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mecamylamine {u} (Compound) treats {v} (Disease) hypertension
Mecamylamine {u} (Compound) binds {v} (Gene) CHRNA2
Mecamylamine {u} (Compound) upregulates {v} (Gene) PLSCR1
Mecamylamine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Mecamylamine {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Autonomic Ganglionic Activity
Mecamylamine {u} (Compound) downregulates {v} (Gene) NPDC1
Mecamylamine {u} (Compound) causes {v} (Side Effect) Fatigue
Mecamylamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tromethamine
Mecamylamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Mecamylamine (Compound) treats hypertension (Disease)
Mecamylamine (Compound) binds CHRNA2 (Gene)
Mecamylamine (Compound) upregulates PLSCR1 (Gene)
Mecamylamine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Mecamylamine (Compound) is included by Decreased Autonomic Ganglionic Activity (Pharmacologic Class)
Mecamylamine (Compound) downregulates NPDC1 (Gene)
Mecamylamine (Compound) causes Fatigue (Side Effect)
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Tromethamine
Mecamylamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine